Supported by the Sun Pharma's proven record of strong cash flows, analysts remain confident in gradual deleveraging over time.
Sun Pharma sees its Organon acquisition as a platform to expand globally, boost in-licensing, and improve long-term efficiencies through a stronger commercial front-end
The Nifty rollovers to May were below average, suggesting a likely cautious stance among participants and slight hesitation to carry forward aggressive bets, says Axis Securities.
Combined entity to have revenue of $12.4 billion; enters biosimilars big league
Sun Pharma's Organon deal lifts stock, but growth concerns and high debt at the acquired firm may cap upside despite synergy potential
Among others, Sun Pharma was the top gainer up over 7 per cent, followed by Gland Pharma, Alkem Laboratories, Zydus Lifesciences and Wockhardt up over 2 per cent
Sun Pharma to acquire all outstanding shares of Organon for $14.00 per share in an all cash transaction with an enterprise valuation of $11.75 billion.
April 26 (Reuters) - India's Sun Pharmaceutical Industries will uy Organon & Co in an all-cash deal, valuing the U.S. drugmaker at about $11.75 billion including ebt, the companies said on Sunday.
Glenmark Pharma, Cipla, Wockhardt, Mankind Pharma, Lupin, Zydus Life, Laurus, Ipca Labs, Divis Labs, Strides Pharma and Onesource were up in the range of 3% to 6%.
Pharma sector may see a 7 per cent Y-o-Y growth in reported sales and a 1 per cent increase in Ebitda, led by steady ex-gRevlimid US sales, healthy domestic growth, and favourable forex movements
Sun Pharma shares fall 5 per cent amid Organon deal buzz and US tariff concerns. Tech charts show the stock has a 'bearish' outlook
Amol Athawale of Kotak Securities believes that the short-term outlook for Nifty Healthcare remains uncertain and sentiment may turn negative in case the index falls below 13,500 levels.
Nifty Pharma index today: The Trump administration may announce new tariffs on drugmakers that have not struck deals guaranteeing low prices in the country
The futures & options market positioning reflects heavy short build-up, creating conditions for sharp but temporary short-covering rallies, says Systematix Institutional Equities.
Companies including Dr. Reddy's Laboratories, Sun Pharma, Zydus Lifesciences, Natco Pharma, Alkem Laboratories, and Torrent Pharmaceuticals have developed their own formulations
Stocks to Watch today, March 17: Reliance Industries, Tata Motors, Sun Pharma, RVNL, GMDC, RailTel, and Sagar Cements are among the top stocks to watch today
In the past one month, the Nifty Pharma index has rallied 4.5 per cent, as against 7.8 per cent decline in the benchmark Nifty 50.
Sun Pharma is transitioning its US business from low-margin generics to high-value specialty and innovative therapies.
Sun Pharma and Hindustan Aeronautics are among the top stock picks by Rajesh Bhosale of Angel One
Thus far in the month of February 2026, Laurus Labs surged 13%, while Sun Pharmaceutical Industries and Torrent Pharmaceuticals soared 11% each.